DepoFoam(TM) technology: A vehicle for controlled delivery of protein and peptide drugs

Journal of Controlled Release

Volumn 64, Issue 1-3, 2000, Pages 155-166

  Ye, Qiang ^a   Asherman, John ^a   Stevenson, Mark ^a   Brownson, Elizabeth ^a   Katre, Nandini V ^a  

^a DepoTech Corporation   (United States)

Author keywords

Controlled release; High loading liposome; Multivesicular liposome; Protein and peptide encapsulation; Sustained delivery

Indexed keywords

DIOLEOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DRUG VEHICLE; FLUORESCEIN ISOTHIOCYANATE; INSULIN; LEUPRORELIN; LIPOSOME; METENKEPHALIN; OCTREOTIDE; PEPTIDE; PROTEIN; RECOMBINANT HUMAN INSULIN; TESTOSTERONE; ENKEPHALIN; PLASMA PROTEIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; MALE; MICROENCAPSULATION; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PLASMA; PRIORITY JOURNAL; RAT; SUSPENSION; TECHNOLOGY; TESTOSTERONE BLOOD LEVEL; ANIMAL; ARTICLE; BLOOD; CHEMISTRY; CONFOCAL MICROSCOPY; DELAYED RELEASE FORMULATION; DRUG STABILITY; ESCHERICHIA COLI; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; METHODOLOGY; TIME;

ANIMALS; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ENKEPHALINS; ESCHERICHIA COLI; HUMANS; INSULIN; LEUPROLIDE; LIPOSOMES; MICROSCOPY, CONFOCAL; OCTREOTIDE; PARTICLE SIZE; PEPTIDES; PROTEINS; RATS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 0033621759     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00146-7     Document Type: Conference Paper

References (41)

1. Lasic D.D. Liposomes: From Physics To Applications. 1993;Elsevier, Amsterdam.
2. Lasic D.D., Papahadjopoulos D. Liposomes revisited. Science. 267:1995;1275-1276.
3. Anderson P.M., Hanson D.C., Hasz D.E., Halet M.R., Blazar B.R., Ochoa A.C. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and Interferon-gamma. Cytokine. 6:1994;92-101.
4. Meyer J., Whitcomb L., Collins D. Efficient encapsulation of proteins within liposomes for slow release in vivo. Biochem. Biophys. Res. Commun. 199:1994;433-438.
5. Mayer L.D., Hope M.J., Cullis P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta. 858:(1):1986;161-168.
6. Cullis P.R., Hope M.J., Bally M.B., Madden T.D., Mayer L.D., Fenske D.B. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta. 1331:(2):1997;187-211.
7. Huang C. Studies on phosphatidylcholine vesicles. Formation and physical characteristics. Biochemistry. 8:(1):1969;344-352.
8. Bangham A.D., Standish N.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13:1965;238-252.
9. Bangham A.D. Lipid bilayers and biomembranes. Annu. Rev. Biochem. 41:1972;753-776.
10. Kim S., Turker M.S., Chi E.Y., Sela S., Martin G.M. Preparation of multivesicular liposomes. Biochim. Biophys. Acta. 728:(3):1983;339-348.
11. Kim S. DepoFoam-mediated drug delivery into cerebrospinal fluid. Methods Neurosci. 21:1994;118-131.
12. Kim T., Murdande S., Gruber A., Kim S. Sustained-release morphine for epidural analgesia in rats. Anesthesiology. 85:(2):1996;331-338.
13. Katre N.V., Asherman J., Schaefer H., Hora M. Multivesicular liposome (DepoFoam™) technology for the sustained delivery of insulin-like growth factor-I (IGF-I). J. Pharm. Sci. 87:(11):1998;1341-1346.
14. Lasic D.D. Liposomes: synthetic lipid microspheres serve as multipurpose vehicles for the delivery of drugs, genetic material and cosmetics. Am. Sci. 80:1992;20-31.
15. Spector M.S., Zasadzinski J.A., Sankaram M.B. Topology of multivesicular liposomes: a model biliquid foam. Langmuir. 12:1996;4704-4708.
16. Heinemann L., Richter B. Clinical pharmacology of human insulin. Diabetes Care. 16:(3):1993;90-100.
17. Hoffman A., Ziv F. Pharmacokinetic Considerations of new insulin formulations and routes of administration. Clin. Pharmacokinet. 33:(4):1997;285-301.
18. Spangler R.S. Insulin administration via liposomes. Diabetes Care. 13:(9):1990;911-922.
19. Okada H., Heya T., Ogawa Y., Shimamoto T. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J. Pharmacol. Exp. Ther. 244:1988;744-750.
20. Dlugi A.M., Miller J.D., Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil. Steril. 54:1990;419-427.
21. Okada H., Doken Y., Ogawa Y., Toguchi H. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm. Res. 2:(8):1994;1143-1147.
22. Hughes J., Kosterlitz H.W., Smith T.W. The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br. J. Pharmacol. 120:(4):1997;428-436.
23. Kuraishi Y., Hirota N., Satoh M., Takagi H. Antinociceptive effects of intrathecal opioids, noradrenaline and serotonin in rats: mechanical and thermal algesic tests. Brain Res. 326:(1):1985;168-171.
24. Lamberts S.W. Acromegaly and its treatment. J. Endocrinol. 155:1997;S49-S51.
25. Pollak M.N., Schally A.V. Mechanisms of antineoplastic action of somatostatin analogs. Proc. Soc. Exp. Biol. Med. 217:(2):1998;143-152.
26. J.M. Olefsky, Personal communication, 1995.
27. Katre N.V., Asherman J., Schaefer H., Hora M. A multivesicular lipid-based sustained-release system for the delivery of therapeutic proteins. Proc. 8th Int. Pharm. Technol. Symp., Turkey :1996;20-21.
28. R.C. Willis, Method for utilizing neutral lipids to modify in-vivo release from multivesicular liposomes, US Patent 5,891,467, 1998.
29. Kim T., Kim J., Kim S. Extended-release formulation of morphine for subcutaneous administration. Cancer Chemother. Pharmacol. 33:1993;187-190.
30. Chatelut E., Suh P., Kim S. Sustained-release methotrexate for intracavitary chemotherapy. J. Pharm. Sci. 83:(3):1994;429-432.
31. Bonetti A., Kim S. Pharmacokinetics of an extended-release human interferon alpha-2b formulation. Cancer Chemother. Pharmacol. 33:1993;258-261.
32. M.B. Sankaram, S. Kim, Multivesicular liposomes with controlled release of encapsulated biologically active substances, US Patent 5,766,627, 1998.
33. S. Kim, S.B. Howell, Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride, US Patent, 5,807,572 1998.
34. Katre N.V., Knauf M.J., Laird W.J. Chemical modification of recombinant interleukin-2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci. USA. 84:(6):1987;1487-1491.
35. Knauf M., Bell D., Hirtzer P., Luo Z., Young Y., Katre N.V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J. Biol. Chem. 263:(29):1988;15064-15070.
36. Katre N.V. The conjugation of proteins with polyethylene glycol and other polymers. Adv. Drug Deliv. Rev. 10:1993;91-114.
37. Cleland J.L., Jones A.J.S. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm. Res. 13:(10):1996;1464-1475.
38. Johnson O., Jaworowicz W., Cleland J., Bailey L., Charnis M., Duenas E., Wu C., Shepard D., Magil S., Last T., Jones A. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res. 14:(6):1997;730-735.
39. Brown L., Siemer L., Munoz C., Langer R. Controlled release of insulin from polymer matrices: In vitro kinetics. Diabetes. 35:1986;684-691.
40. J.M. Anderson, Personal communications, 1995.
41. Chamberlain M.C., Khatibi S., Kim J.C., Howell S.B., Chatelut E., Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). Arch. Neurol. 50:1993;261-264.